L J Egan

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Gastroesophageal reflux disease in pregnancy
    Raja Affendi Raja Ali
    University College Hospital, Galway, Ireland
    Best Pract Res Clin Gastroenterol 21:793-806. 2007
  2. ncbi Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
    L J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 274:26448-53. 1999
  3. ncbi CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms
    L J Egan
    Clinical Pharmacology Unit, Division of Gastroenterology and Hepatology and Division of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Aliment Pharmacol Ther 17:1521-8. 2003
  4. ncbi Advances in the treatment of Crohn's disease
    Laurence J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 126:1574-81. 2004
  5. ncbi Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid
    Laurence J Egan
    Gastroenterology Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 2:725-30. 2004
  6. ncbi The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients
    Jean-Frederic Colombel
    Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Gastroenterology 126:19-31. 2004
  7. ncbi The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease
    Brian D Juran
    Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 4:822-30. 2006
  8. ncbi Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes
    Picha Moolsintong
    Department of Internal Medicine and Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Inflamm Bowel Dis 11:1080-4. 2005
  9. ncbi Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastrointest Endosc 68:255-66. 2008
  10. ncbi Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis
    Laurence J Egan
    Department of Pharmacology, National University of Ireland, Clinical Science Institute, University College Hospital, Galway, Ireland
    Curr Gastroenterol Rep 7:485-91. 2005

Research Grants

  1. IKK Beta In Intestinal Inflammation
    Laurence Egan; Fiscal Year: 2005
  2. NF-kB in the intestinal radiation response
    Laurence Egan; Fiscal Year: 2005

Collaborators

Detail Information

Publications11

  1. ncbi Gastroesophageal reflux disease in pregnancy
    Raja Affendi Raja Ali
    University College Hospital, Galway, Ireland
    Best Pract Res Clin Gastroenterol 21:793-806. 2007
    ..Rarely, promotility agents are used. Initiation of these medications must be undertaken after a careful discussion of risks and benefits with patients. In patients without a prior history of reflux, symptoms usually abate after delivery...
  2. ncbi Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
    L J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 274:26448-53. 1999
    ..These findings highlight the importance of inducible phosphorylation of RelA in the control of NF-kappaB activity...
  3. ncbi CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms
    L J Egan
    Clinical Pharmacology Unit, Division of Gastroenterology and Hepatology and Division of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Aliment Pharmacol Ther 17:1521-8. 2003
    ..It is not known if CYP2C19 variant alleles affect responses to proton-pump inhibitor therapy in gastro-oesophageal reflux disease (GERD)...
  4. ncbi Advances in the treatment of Crohn's disease
    Laurence J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 126:1574-81. 2004
    ....
  5. ncbi Drug interactions in gastroenterology: mechanisms, consequences, and how to avoid
    Laurence J Egan
    Gastroenterology Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 2:725-30. 2004
    ..This review describes some examples of common drug interactions in gastroenterology. The underlying mechanisms are discussed, and strategies are proposed to avoid drug interactions in clinical practice...
  6. ncbi The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients
    Jean-Frederic Colombel
    Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Gastroenterology 126:19-31. 2004
    ..However, clinicians must be vigilant for the occurrence of infrequent but serious events, including serum sickness-like reaction, opportunistic infection and sepsis, and autoimmune disorders...
  7. ncbi The AmpliChip CYP450 test: principles, challenges, and future clinical utility in digestive disease
    Brian D Juran
    Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 4:822-30. 2006
    ..An understanding of the principles and opportunities provided by this new category of diagnostic test is key before planning the necessary studies to evaluate the usefulness of AmpliChip CYP450 in gastroenterologic clinical practice...
  8. ncbi Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes
    Picha Moolsintong
    Department of Internal Medicine and Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Inflamm Bowel Dis 11:1080-4. 2005
    ..A small proportion of patients remained idiopathic...
  9. ncbi Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastrointest Endosc 68:255-66. 2008
    ..With the introduction of new techniques to image the small bowel, there remains uncertainty about their role for diagnosing Crohn's disease...
  10. ncbi Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis
    Laurence J Egan
    Department of Pharmacology, National University of Ireland, Clinical Science Institute, University College Hospital, Galway, Ireland
    Curr Gastroenterol Rep 7:485-91. 2005
    ....
  11. ncbi A nudge in the right direction: shaping the metabolic fate of thiopurines for therapeutic gain
    Laurence J Egan
    Clin Gastroenterol Hepatol 5:170-1. 2007

Research Grants2

  1. IKK Beta In Intestinal Inflammation
    Laurence Egan; Fiscal Year: 2005
    ..abstract_text> ..
  2. NF-kB in the intestinal radiation response
    Laurence Egan; Fiscal Year: 2005
    ..These results will provide mechanistic insight into an important medically relevant problem, amd will point the way towards novel therapies to prevent radiation injury to the intestines. ..